Find a UK-based prescribing clinician for medical cannabis.
The Chemistry of Decarboxylation
- Decarboxylation is a chemical reaction that removes a carboxyl group (–COOH) from a molecule, releasing CO₂
- In cannabis, heat converts THCA (non-psychoactive) to THC (psychoactive) and CBDA to CBD
- The reaction occurs at temperatures above approximately 100°C — optimised around 110–120°C over extended time or 150°C briefly
- Vaporisation, combustion, and the manufacturing of cannabis oil products all involve decarboxylation
The concept of decarboxylation is one of the most important pieces of basic science for both patients and clinicians to understand. It explains why raw cannabis leaf added to food or juice has minimal psychoactive effect, why a freshly dried cannabis flower tastes different from vaporised cannabis, and why cannabis oil products must be processed at heat to activate their therapeutic potential. A patient who understands decarboxylation is better equipped to use their medication correctly and to interpret product documentation accurately.
THCA vs THC: Clinical Relevance of the Acidic Precursor
- THCA is present in unheated or poorly decarboxylated cannabis products — it is non-intoxicating
- THCA does have biological activity: anti-inflammatory, neuroprotective, and antiemetic properties independent of CB1 activation
- Some patients specifically seek THCA-rich preparations for these effects without psychoactivity
- Standard CoA reporting includes both THCA and THC; total THC is calculated as: THCA × 0.877 + THC
The CoA calculation of total THC (Total THC = THCA × 0.877 + THC) accounts for the fact that THCA partially converts to THC during vaporisation. This formula is important for prescribers to understand because it means the “available THC” content of a dried flower product is higher than the native THC figure alone suggests. Prescribers who rely only on the native THC percentage may underestimate the total psychoactive potential of the product.
Decarboxylation in Manufactured Cannabis Products
- Oil extractions typically involve decarboxylation as part of the manufacturing process — most oils contain predominantly activated THC and CBD
- Capsules and edibles are fully decarboxylated — bioavailability is determined by the oil carrier and GI absorption
- Tinctures may be partially decarboxylated — check product documentation for the THCA:THC ratio
- Vaporisation of dried flower: decarboxylation occurs in the vaporiser chamber at the set temperature
The decarboxylation status of a product has direct implications for onset of action and potency. Fully decarboxylated oral preparations are the most predictable in terms of dose-response, because the THC content is entirely in its active form before administration. Dried flower products, where decarboxylation occurs during vaporisation, are more variable — vaporiser temperature, airflow, and packing density all affect the efficiency of conversion.
Temperature and Decarboxylation Efficiency
- 100°C: minimal decarboxylation — relevant for very low-temperature vaporisation
- 150–160°C: significant decarboxylation, 80–90% conversion efficiency
- 185–200°C: typical vaporisation range — near-complete decarboxylation with good terpene preservation
- Above 220°C: combustion begins, terpenes degrade rapidly, harmful combustion products generated
Vaporiser temperature guidance is a practical application of decarboxylation chemistry that pharmacists and prescribers should communicate to patients. The optimal vaporisation temperature balances maximal cannabinoid activation with preservation of the terpene profile that contributes to therapeutic effect. Lower temperatures preserve more volatile terpenes; higher temperatures activate more cannabinoids. Most patients benefit from a stepped approach, starting at 185°C and moving up to 200°C during the session.
